EFFICACY & SAFETY

Experts discuss the outcomes of the NATALEE trial for patients with stage II/III HR+/HER2- eBC at high risk of recurrence

Drs Gadi, Dent, and Cohen have been compensated for their time by Novartis Pharmaceuticals Corporation.

eBC, early breast cancer; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive.

Overview of efficacy and safety in the NATALEE trial

Watch an expert panel of four medical oncologists discuss the NATALEE trial, including efficacy and safety data that led to the approval of KISQALI in the adjuvant setting.

Drs Yardley, Seneviratne, Krie, and Hart have been compensated for their time by Novartis Pharmaceuticals Corporation.

RISK OF RECURRENCE

Risk of recurrence in HR+/HER2- eBC and the NATALEE trial design

Four expert medical oncologists discuss unmet medical needs in the eBC landscape, including risk of recurrence, and review the study design and patient population included in the pivotal phase III NATALEE trial.

Drs Yardley, Seneviratne, Krie, and Hart have been compensated for their time by Novartis Pharmaceuticals Corporation.

PATIENT MANAGEMENT

Patient management and support with KISQALI in eBC

Hear perspectives from an expert panel of medical oncologists on how to optimize patient management and access support resources for patients treated with KISQALI in the adjuvant setting.

Drs Yardley, Seneviratne, Krie, and Hart have been compensated for their time by Novartis Pharmaceuticals Corporation.